NuVasive (NASDAQ: NUVA) reported Q2 EPS of $0.40, $0.04 better than the analyst estimate of $0.36. Revenue for the quarter came in at $236.5 million versus the consensus estimate of $233.01 million.

GUIDANCE:

NuVasive sees FY2016 EPS of $1.64, versus the consensus of $1.51. NuVasive sees FY2016 revenue of $962 million, versus the consensus of $936 million.

"NuVasive delivered another strong quarter, outperforming the spine market to deliver double-digit revenue growth, expanding our operating profitability year-over-year and delivering earnings growth of 28%," said Gregory T. Lucier, chairman and chief executive officer of NuVasive. "Our results were driven by strong growth in our international business, which benefitted from our continued revitalization efforts, and strength in our U.S. spinal hardware business, where adoption of our integrated Global Alignment platform drove momentum in sales of our procedurally integrated solutions. With this growth in our geographies and businesses for the first half of the year, and the addition of the Biotronic NeuroNetwork business, we are raising our full year guidance for 2016."

For earnings history and earnings-related data on NuVasive (NUVA) click here.